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Figure 1
were no statistically signiﬁcant group differences for any of the secondary
patient-reported outcomes at week 68.
Conclusions: A signiﬁcant weight reduction improves the knee OA patients’
symptoms, as a high proportion of patients experience an OMERACT-OARSI
response at 16 weeks. However, although the sustainability of weight loss
was signiﬁcantly better in the diet group, this trial did not provide any
evidence of a difference between continuous attention from a dietician
following a 1-year maintenance program compared to either exercise or
‘nothing’ in terms of treating OA symptoms.
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Purpose: Hyaluronic acid (HA) has been included in European League
Against Rheumatology, Osteoarthritis Research Society International, Amer-
ican College of Rheumatology, American Pain Society and American
Academy of Orthopedic Surgeons recommendations for treatment of
painful knee osteoarthritis (OA). Intra-articular (IA) sodium hyaluronate
has proven eﬃcacious and well tolerated for the treatment of pain as-
sociated with knee OA, but optimal molecular weight of HA and dosing
regimen is still not known. HYADD4-G is a novel hydrogel obtained with a
new linear (not cross- linked) derivative of HA of bacterial origin (partial
hexadecylamide of 500-730 kDa hyaluronic acid Pat. No. EU 1095064) that
shows higher viscoelastic properties than the native HA with preservation
of hyaluronan biocompatibility.
The study objective was to evaluate the eﬃcacy and tollerability of 2
different HYADD4-G dosing regimens (2 versus 3 i.a. injections) against
phosphate-buffered saline (PB-Saline) up to 6 months in patients with knee
OA.
Methods: Prospective, multicentre, parallel, randomized, double-blind
(masked observed), PB-Saline controlled, 6 months study in knee OA.
Patients: primary knee OA according to ACR criteria, Kellgren-Lawrence
II-III stage, pain on walking >40 mm on VAS at baseline. Primary outcome
measure: pain during 50 ft (15 m) walk test, measured by Visual Ana-
logue Scale (VAS) at visits 2-9. Statistical Analysis: eﬃcacy evaluated in
intent-to-treat (ITT) population. Two-sided superiority tests of 2 different
regimens of HYADD4-G vs PB-saline for all primary and secondary outcome
measures.
Results: A total of 439 patients were randomized either to HYADD4-G 2 inj.
group (n=145), HYADD4-G 3 inj. (n=150) and PB-saline (n=144). There were
no signiﬁcant differences in demographic and disease activity parameters
between groups at baseline. Symptomatic outcome measures showed a
signiﬁcant improvement from baseline in the three treatment groups. In
particular, considering the HYADD4-G 2 injections group, the mean change
(%) between baseline and ﬁnal visit for the 50 ft walk test (VAS) was -36,5
mm (-58,9%), for WOMAC pain -19,8 mm (-40,4%), for WOMAC Stiffness
-20,5 mm (-27,1%), and for WOMAC physical function -18,2 mm (-35,4%).
However, due to a huge and unexpected placebo response, for primary and
secondary endpoints, no statistically signiﬁcant differences between the
treatment groups at any of the Visits 5 to 9 were observed. In exploratory
sub-group analysis of patients with age <65 years the pain in the target
knee was improved from baseline Visit 2 to Visit 5 in all treatment groups.
The comparison regarding pain in the target knee during walk test between
the HYADD4-G 2 injections group and the PB-Saline group for patients <65
years revealed the following p-values: P=0,1561 at the ﬁrst visit after the
last injection (day 28), P=0,0267 at day 60, P=0,0397 at day 90, P=0,0499 at
day 120, and P=0,3329 at day 180 (2-sided t-test).
There were no clinically relevant and/or statistically signiﬁcant differences
between the treatment groups with regard to frequency, distribution, inten-
sity, premature termination, or seriousness, but for probable relationship
to study group and occurrence of AEs in target knee.
Conclusions: New HA formulations HYADD4-G were effective and well
tolerated in symptomatic treatment of painful knee OA. The reductions in
VAS knee pain for patients <65 years were signiﬁcantly more effective in
HYADD4-G given in a 2 IA injections than PB-saline. A clinically signiﬁ-
cant decrease in analgesic consumption, was also observed in the same
HYADD4-G study group.
Keywords: osteoarthritis, hyaluronic acid, IA therapy.
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Purpose: To compare the eﬃcacy and safety of 2 proprietary based Chon-
droitin Sulphate medicinal products: Structum® 1000mg and Chondrosulf®
1200mg.
Methods: Multicentre, randomized, double-blind, double placebo, active
controlled, parallel-group study, conducted according to a non-inferiority
design. Patients aged 50-80 years with symptomatic KOA (ACR criteria)
were randomized to receive during 24 weeks either Structum 500mg BID
or Chondrosulf 400mg TID. Inclusion criteria were: global pain in the
target knee ≥ 40 mm on a 100-mm visual analog scale (VAS), Lequesne’s
Algofunctional Index (LFI) score > 7 (range: 0-24) and radiological Kellgren-
Lawrence grade 2 or 3. The primary outcome was the mean variation over
24 weeks of the global pain (VAS) and LFI score. Main secondary outcomes
were patient’s and physician’s global assessments, Omeract-OARSI respon-
ders rate, concomitant analgesics intake and quality of life (SF-12). Safety
was assessed by recording any adverse events (AE). A non-inferiority test
was performed: 95% conﬁdence interval (CI) of the difference Structum -
Chondrosulf on change of VAS and LFI scores. Predeﬁned non inferiority
limit was settled as the lower limit of the 95% CI above -5mm and -1pt
respectively for VAS and LFI scores.
Results: 837 patients were randomized: 817 analyzed in the full analysis
dataset (FAS), 692 in the per protocol (PP) analysis with no difference be-
tween groups at entry regarding demographics and disease characteristics.
The main eﬃcacy analysis (PP) showed no difference between the 2 groups
on the mean variations of pain VAS or LFI scores over 24 weeks which
varied for VAS and LFI scores by -23,9 (17,5) and -3,2 (2,4) respectively in
Structum group and by -23,8 (17,2) and -3,1 (2,4) in Chondrosulf group.
Differences for VAS and LFI were respectively 0.01 [IC95%: -2,6; 2,6] and
0,139 [IC95%: -0,2; 0,5]. The lower limit of the 2 CI were above the prede-
ﬁned non inferiority margins (-5 and -1 respectively), clearly demonstrating
the non inferiority of Structum compared to Chondrosulf. The analysis on
the FAS gave similar results. Analyses of the secondary eﬃcacy outcomes
(PP and FAS) populations showed the same trends for each treatment
with improvements of clinical relevance at W24. The overall improvement
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(pain and function) translated into an improvement of SF12 physical
component. Improvement was achieved as from W6 and maintained up to
W24. Changes of the VAS and LFI score between baseline and W24 were
respectively -29,0 (21,9) and -4,1 (3,1) in Structum group and -29,9 (22,3)
and -4,1 (3,2) in Chondrosulf group. OMERACT-OARSI responders rates at
week 24 were 76,3% in Structum and 73,8% in Chondrosulf group (PP).
Rescue medication use (paracetamol and/or NSAIDs) was low and similar
in the 2 groups. 37.4% and 33.1% in the Structum and in the Chondrosulf
group respectively did not take any rescue medication. Both treatments
were well tolerated with a discontinuation rate for safety of 2.4% in the
Structum group and 4.5% in Chondrosulf group.
Conclusions: Structum® 1000mg (500mg BID) and Chondrosulf® 1200mg
(400mg TID) were equally effective on pain relief and functional improve-
ment in patients with symptomatic knee OA over a 6 month period of
time. The improvement started as early as week 6 and persists over the 24
weeks. Eﬃcacy was also conﬁrmed by the high rate of responders, around
75% in each group.
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Purpose: Selective COX-2 inhibitors are frequently used in treatment of
osteoarthritis (OA) to control inﬂammation and relieve pain. In vitro and
ex vivo research using human articular cartilage, demonstrated an inﬂam-
mation independent chondroprotective effect of celecoxib. Such effects are
diﬃcult to verify in clinical trials because changes in OA cartilage, degen-
erative and reparative, are slow and evaluation by image and biomarker
techniques are still hampered by their limited sensitivity. Therefore, pa-
tients were treated in vivo several weeks prior to joint replacement surgery.
At the moment of surgery, cartilage was obtained and analyzed ex vivo
in detail. Three recent small studies using this approach demonstrated a
beneﬁcial effect of celecoxib at chondrocyte mRNA and protein level, and
at the level of matrix integrity suggesting disease modifying characteristics
of celecoxib.
These positive results tempted us to perform a well designed and powered
RCT to evaluate the disease modifying properties of celecoxib in treatment
of end-stage OA.
Methods: Patients (n=172) with end-stage knee OA on the waiting list for
knee replacement surgery were randomized to 4 groups and treated for at
least 4 weeks prior to surgery: celecoxib 2dd200mg, naproxen 2dd250mg
stopped 3 days prior to surgery (because of its platelet-inhibiting effect),
celecoxib 2dd200mg also stopped 3 days prior to surgery, or no treatment.
Cartilage and synovial tissue were collected during surgery and analyzed
in detail ex vivo fully blinded to the treatment until all data were ob-
tained. Primary outcome was cartilage proteoglycan release. Additionally,
several biochemical markers of cartilage integrity and synovial inﬂamma-
Abstract 329 – Table 1. Changes in Proprioception scores
Variable Mean Scores (SD) Change from BaselineMean (SD) Total Number of Subjects P-value Tai Chi vs. Control
Tai Chi (N=20) Control (N=20) Tai Chi Control
30 Degrees
Baseline 5.58 (4.15) 4.26 (2.88)
Week 12 3.00 (2.55) 6.55 (4.38) -2.53 (5.22) 2.11 (5.64) 40 0.01
Week 24 3.60 (4.58) 3.80 (2.50) -2.58 (5.84) -0.68 (2.60) 40 0.20
Week 48 4.10 (2.79) 4.79 (4.70) -1.26 (4.75) -0.11 (4.42) 39 0.40
45 Degrees
Baseline 4.60 (4.03) 3.63 (3.08)
Week 12 4.00 (3.29) 4.75 (4.12) -0.60 (5.06) 0.95 (5.04) 40 0.30
Week 24 2.75 (2.59) 1.65 (1.73) -1.85 (4.40) -1.95 (3.27) 40 0.90
Week 48 2.75 (1.55) 3.00 (2.98) -1.85 (4.52) -1.22 (4.41) 39 0.70
60 Degrees
Baseline 3.05 (3.05) 3.24 (2.93)
Week 12 2.45 (2.44) 2.84 (2.61) -0.60 (4.03) 0.06 (3.80) 39 0.60
Week 24 1.94 (2.46) 3.60 (3.31) -1.18 (3.28) -0.88 (3.76) 27 0.80
Week 48 3.21 (2.44) 1.94 (1.89) 0.26 (4.59) -1.44 (4.11) 37 0.30
tion were determined. The WOMAC questionnaire was used to evaluate
pain, stiffness and function before and after treatment. The study was
conducted according to the declaration of Helsinki and registered EudraCT
nr 2007-004862-41.
Results: 4 patients withdrew their consent, 10 changed medications within
2 weeks, and of 20 patients insuﬃcient tissue was obtained. Drop-outs
were equally distributed over the 4 treatment arms. Data were analyzed
by intention to treat as well as per protocol of the remaining 138 pa-
tients. At inclusion, age, gender, weight (BMI) and cartilage damage (X-ray,
macroscopic or histological) did not differ between the 4 randomized
groups. Unexpectedly, cartilage proteoglycan release was not different
between the 4 treatments. Also the other biochemical cartilage parameters
did not differ between the 4 groups. Furthermore, prostaglandin-E2 and
nitric oxide (NO) levels produced by the cartilage remained unchanged
compared to the no-treatment group. The ex vivo release of inﬂammatory
mediators IL-1β, TNFα, PGE2 and NO by the synovial tissue only showed a
statistical signiﬁcant decrease in NO levels in the celecoxib treated group
compared to the no-treatment group. Celecoxib treatment showed a slight
improvement in WOMAC pain (p<0.01), function and total score compared
to the no-treatment group.
Conclusions: No clear effect of celecoxib treatment on cartilage was evident
in the present study. Also the effects on synovial inﬂammatory mediators
were limited. Only a small beneﬁcial effect on WOMAC scores was found.
As such the reported in vivo disease modifying effects of celecoxib could
not be conﬁrmed in a suﬃciently powered single blinded RCT.
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CONTROLLED TRIAL
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Tufts Med. Ctr., Boston, MA
Purpose: Neurologic deﬁcits, especially quadriceps sensory dysfunction
(i.e., decreased proprioceptive acuity) may precede Knee Osteoarthritis
(KOA) and are proposed to be a factor in its pathogenesis or progression.
Tai Chi may provide ideal proprioceptive exercise to older individuals
with KOA through its emphasis on balance, muscle strengthening, and
integration of the mind and body. Previous long-term observational stud-
ies found that Tai Chi practitioners had better knee-joint proprioceptive
acuity versus controls in an older population. We evaluated the effects of
Tai Chi for knee-joint proprioception in KOA in a randomized controlled
trial.
Methods: We randomized 40 eligible individuals (age > 55, BMI ≤ 40
kg/m2 with knee pain on most days of the previous month and tibiofemoral
OA K/L grade ≥2) to Tai Chi (10 modiﬁed forms from classical Yang style)
or an attention control (stretching and wellness education). The 60-minute
intervention sessions occurred twice-weekly for 12 weeks. The knee joint
proprioception was measured using a Biometrics™ electrogoniometer with
an ADU301 angle display unit during each assessment visit. Three test
angles (30, 45 and 60 degrees) were evaluated with each subject in a
sitting position taken as neutral (0 degree). The electrogoniometer was
placed longitudinally in alignment with the femur and tibia with double-
